Wegovy and Cardiovascular Risk: The SELECT Findings

Wegovy is licensed in the UK to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight (BMI 27+). This is based on the SELECT trial, in which around 8,800 people were treated for a median of over three years. The NHS reflects this: semaglutide may be offered to people with obesity or overweight who have had a heart attack or stroke, or have peripheral arterial disease.

Beyond weight loss, Wegovy now carries a cardiovascular indication, reflecting trial evidence that it can reduce the risk of serious cardiovascular events in certain people. This is a genuine, licensed use rather than an off-label claim, and it is worth understanding who it applies to and what the evidence behind it is.

This guide explains Wegovy's cardiovascular indication and the SELECT trial behind it, who it applies to, and how it fits with weight management. It draws on the UK Summary of Product Characteristics and the NHS. It is general information; whether this applies to you is a decision for your prescriber.

Wegovy now has a cardiovascular indication

In addition to weight management, the Wegovy SmPC includes a cardiovascular risk reduction indication: it is indicated, alongside a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (a BMI of 27 or above)¹. So this is a licensed UK use ¹.

The 'major adverse cardiovascular events' the indication refers to are cardiovascular death, non-fatal heart attack (myocardial infarction) and non-fatal stroke¹. So it is about reducing the risk of these specific serious events ¹.

This is a genuine, evidence-based indication, not a marketing claim, and it is based on the SELECT trial described below ¹. The sections that follow explain the evidence and who it applies to ¹.

This matters because it changes how Wegovy can be thought of for some people ¹. For someone with both excess weight and established heart disease, it is not only a weight-management medicine but one with an evidenced cardiovascular benefit in that group, which can be part of why a clinician considers it ¹. At the same time, it is worth being precise that this is a defined, evidence-backed indication, distinct from the looser online claim that weight-loss medicines are simply 'good for the heart', which is vaguer and not the same thing ¹.

What the SELECT trial was

The cardiovascular indication is based on the SELECT cardiovascular outcomes trial. In it, around 8,800 people with established cardiovascular disease and obesity or overweight were treated with Wegovy, for a median of about 37 months (over three years), with a similar number on placebo ¹.

This is a large, long trial specifically designed to look at cardiovascular outcomes rather than just weight, which is why it can support a cardiovascular indication ¹. The detailed results sit in the clinical sections of the SmPC ¹.

So the indication rests on a substantial body of evidence in the relevant population, people with existing cardiovascular disease and excess weight, followed over years ¹. That is what distinguishes a licensed cardiovascular indication from a general assumption ¹.

This guide does not quote a specific figure for the size of the risk reduction, because the precise hazard ratio or percentage was not in the SmPC text available here ¹. What can be said accurately is that the trial supported a licensed claim of reduced risk of those major events in the studied group, which is what the indication reflects ¹. For the exact numbers, the full SmPC or a clinician is the right source, and this guide stays within what it can verify ¹.

Who this applies to

The cardiovascular indication is specifically for adults with established cardiovascular disease and obesity or overweight (BMI 27 or above)¹. So it is not a general claim for everyone taking Wegovy; it applies to that defined group ¹.

The NHS reflects this in patient terms: it notes you may be offered semaglutide if you are living with obesity or overweight and have had a heart attack or stroke, or have peripheral arterial disease (a condition affecting blood flow in the legs) ². So the NHS describes the same kind of established-cardiovascular-disease population ².

If you do not have established cardiovascular disease, this particular indication does not apply to you, though Wegovy's weight-management indication may, depending on your BMI and circumstances ¹². Which applies is for your prescriber to assess ¹.

It is worth understanding what 'established cardiovascular disease' broadly means here, since it defines the group ¹². The NHS framing, having had a heart attack or stroke, or having peripheral arterial disease, captures the idea: it is people who already have diagnosed cardiovascular disease, not those who simply have risk factors for it ¹². So the indication is targeted at a higher-risk group in whom reducing the chance of a further serious event is the goal, rather than at the general weight-management population ¹².

Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.

How it fits with weight management

The cardiovascular indication does not replace the weight-management one; it sits alongside it ¹. In both, the medicine is used as an adjunct to a reduced-calorie diet and increased physical activity, so the lifestyle foundation remains central ¹.

For someone with established cardiovascular disease and excess weight, the two purposes overlap: the medicine supports weight management and, in that population, reduces the risk of the major cardiovascular events above ¹. So it can serve both ends in the right person ¹.

It is still the same medicine, with the same dosing, side effects and cautions covered in our guide on how Wegovy works¹. The cardiovascular indication is about an additional, evidenced benefit in a defined group, not a different product ¹.

That overlap can be genuinely valuable for the right person ¹. Someone with established heart disease and obesity faces both the risks of excess weight and of further cardiovascular events, and a single medicine that addresses the weight and, in that group, reduces cardiovascular risk can be an efficient part of their care ¹. But it remains the same Wegovy with the same considerations, used as an adjunct to diet and activity, rather than a special cardiovascular formulation ¹.

What this does and does not mean

It is worth being clear about scope. The indication means Wegovy is licensed to reduce the risk of major cardiovascular events in the defined group; it does not mean it prevents them in everyone or replaces other cardiovascular treatments ¹. Risk reduction is not a guarantee ¹.

So someone in this group would typically still have their other cardiovascular care (such as medicines for blood pressure or cholesterol) managed as usual, with Wegovy adding to rather than substituting for that ¹². Do not stop other cardiovascular medicines on the assumption that Wegovy replaces them ².

This is a decision for the clinician managing your cardiovascular risk, who can weigh whether the indication applies to you and how it fits your overall care ¹². The indication is an addition to the toolkit, used in the right person ¹.

It is also worth holding the benefit and the risks together honestly ¹. Wegovy still has its usual side effects and cautions, the gut effects, pancreatitis and gallstone cautions, and the rest, and these apply whether it is used for weight management or cardiovascular risk ¹. So the cardiovascular benefit in the defined group is weighed against the medicine's known profile, as with any treatment, which is part of why the decision sits with a clinician who knows your full picture ¹². In the right person, the cardiovascular benefit can tip that balance in its favour ¹.

What to discuss with your prescriber

If you have established cardiovascular disease and obesity or overweight, it is worth discussing with your prescriber whether Wegovy's cardiovascular indication is relevant to you, alongside its weight-management role ¹². They can assess whether you fit the defined group ¹.

Cover your full cardiovascular history and other medicines, since Wegovy would add to, not replace, your existing care, and continue those other treatments unless advised otherwise ¹². The usual Wegovy considerations, dosing, side effects and cautions, still apply ¹. Stopping a statin or other cardiovascular medicine on the assumption Wegovy replaces it could leave your risk undertreated, so any change is for the prescriber managing it ².

Our guide on how Wegovy works covers the medicine more broadly. For cardiovascular risk, the headline is that Wegovy is licensed, based on the SELECT trial, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, as an addition to rather than a replacement for the rest of your cardiovascular care ¹².

Frequently asked questions

Is Wegovy licensed to reduce cardiovascular risk?

Yes. The Wegovy SmPC includes a cardiovascular indication: alongside diet and activity, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight (BMI 27+) ¹. It is based on the SELECT trial ¹.

What was the SELECT trial?

A large cardiovascular outcomes trial in which around 8,800 people with established cardiovascular disease and obesity or overweight were treated with Wegovy for a median of about 37 months ¹. It was designed to look at cardiovascular outcomes, which is why it supports the cardiovascular indication ¹.

Who can Wegovy's cardiovascular indication help?

Adults with established cardiovascular disease and obesity or overweight (BMI 27+) ¹. The NHS notes semaglutide may be offered to people with obesity or overweight who have had a heart attack or stroke, or have peripheral arterial disease ². It does not apply to those without established cardiovascular disease ¹.

Does Wegovy prevent heart attacks and strokes?

It is licensed to reduce the risk of major cardiovascular events in the defined group, based on SELECT, but reducing risk is not the same as preventing them in everyone, and it does not replace other cardiovascular treatments ¹. It adds to, rather than substitutes for, existing care ¹².

Should I stop my heart or blood pressure medicines if I take Wegovy?

No. Wegovy adds to rather than replaces your existing cardiovascular care, so continue other medicines unless your prescriber advises otherwise ¹². The cardiovascular indication is an addition to the toolkit in the right person, not a substitute for the rest of your treatment ¹.

Is this the same Wegovy used for weight loss?

Yes, it is the same medicine, with the same dosing, side effects and cautions ¹. The cardiovascular indication sits alongside the weight-management one, both used as an adjunct to diet and activity; it is an additional evidenced benefit in a defined group, not a different product ¹.

Your next step

Wegovy is licensed in the UK to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial of around 8,800 people followed for a median of over three years. The NHS reflects this for people who have had a heart attack or stroke, or have peripheral arterial disease.

If you have established cardiovascular disease and excess weight, discuss with your prescriber whether this indication is relevant to you alongside Wegovy's weight-management role. It reduces risk rather than guaranteeing prevention, and adds to rather than replaces your other cardiovascular care, so continue those treatments unless advised otherwise. It remains the same Wegovy with the same side effects and cautions, weighed against the benefit by a clinician who knows your full picture, and in the right person that evidenced benefit can tip the balance in its favour alongside its weight-management role, as part of, not a substitute for, their wider cardiovascular care, which should continue as before unless their prescriber advises otherwise. The point worth holding onto is that this is a licensed UK indication backed by a large trial, not an off-label hope, so it is a reasonable thing to raise and have assessed properly rather than something you would have to argue for against the evidence.

Disclaimer

This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.

If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.

If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.

References

1. Wegovy SmPC 4.1 (cardiovascular risk reduction indication: MACE in adults with established CVD and obesity/overweight BMI>=27) and 4.8/5.1 (SELECT: ~8,800 patients, median ~37 months)
2. Semaglutide (may be offered if living with obesity/overweight and have had a heart attack or stroke, or have peripheral arterial disease)